Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Sponsor

Stanford University (Other)

Overall Status

Recruiting

CT.gov ID

NCT04768426

Collaborator

(none)

Enrollment

Location

Arm

59.9

Anticipated Duration (Months)

0.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of the study is to evaluate the use of a circulating tumor DNA (ctDNA) assay, ie, a "liquid biopsy," as a tool to identify triple-negative breast cancer (TNBC) patients who will or will not experience benefit from treatment with capecitabine. Participants will be monitored for changes in ctDNA in the blood over time received during capecitabine treatment. Results of ctDNA analysis will be correlated to genetic characteristics of individual tumors. This may inform future clinical trials in which patients could receive a different treatment than capecitabine to reduce their risk of breast cancer relapse.

Condition or Disease	Intervention/Treatment	Phase
Triple Negative Breast Cancer Breast Cancer	Drug: Capecitabine	Phase 2

Detailed Description

The Primary Objective is to characterize the circulating tumor DNA (ctDNA) profile of triple-negative breast cancer (TNBC) in participants with residual disease after standard neoadjuvant chemotherapy (NAC) receiving standard-of-care adjuvant capecitabine.

The Secondary Objectives are to correlate ctDNA levels with genomic features and survival.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

25 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase II Trial of Circulating Tumor DNA Monitoring During Adjuvant Capecitabine in Patients With Triple-negative Breast Cancer and Residual Disease Following Standard Neoadjuvant Chemotherapy

Actual Study Start Date :

Feb 3, 2021

Anticipated Primary Completion Date :

Feb 1, 2026

Anticipated Study Completion Date :

Feb 1, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Capecitabine 1000 mg/m2 administered on Days 1 to 14 of 21-day cycles	Drug: Capecitabine 1000 mg/m2 administered on Days 1 to 14 of 21-day treatment cycles, for 8 cycles. Other Names: fluoropyrimidine carbamate

Arm

Intervention/Treatment

Experimental: Capecitabine

1000 mg/m2 administered on Days 1 to 14 of 21-day cycles

Drug: Capecitabine

1000 mg/m2 administered on Days 1 to 14 of 21-day treatment cycles, for 8 cycles.

Other Names:

fluoropyrimidine carbamate

Outcome Measures

Primary Outcome Measures

Baseline levels of ctDNA detection [6 months]
In participants with triple-negative breast cancer (TNBC) who have received standard neoadjuvant chemotherapy (NAC), levels of circulating tumor DNA (ctDNA) will be assessed at baseline and after 6 months of standard adjuvant capecitabine treatment. The outcome will be reported as the number of participants who are: ctDNA+ (ctDNA-positive) at baseline and at 6 months. ctDNA+ at baseline but ctDNA- (ctDNA-negative) at 6 months. ctDNA- at baseline and at 6 months. ctDNA- at baseline but ctDNA+ at 6 months. The outcome is a number without dispersion.

Secondary Outcome Measures

Correlation of ctDNA levels with genomic features of tumor [24 weeks]
Genomic status of certain mutations in the tumor will be assessed by next-generation sequencing in participants who are: ctDNA+ (ctDNA-positive) at baseline and at 6 months. ctDNA+ at baseline but ctDNA- (ctDNA-negative) at 6 months. ctDNA- at baseline and at 6 months. ctDNA- at baseline but ctDNA+ at 6 months. The genes of interest are: PIK3CA AKT AKT1 PTEN BRCA1 BRCA2 PALB2 CHEK2 ATM NBN BRIP1 BARD1 MRE11 ATR RAD50 RAD51C RAD51D FANCA FANCC FANCD2 FANCE FANCF FANCG FANCL. The outcome will be reported as the number of participants with a positive mutation status in the gene of interest. The outcome is a number without dispersion.
Overall Survival (OS) [5 years]
Overall survival (OS) will be assessed as participants remaining alive 5 years from the first treatment initiation. The outcome is reported as the number of participants alive (without dispersion).
Relapse-Free Survival [5 years]
Relapse-free survival is defined as the time from treatment initiation to first invasive relapse or death, through 5 years. The outcome is reported as the number of participants with relapse-free survival (without dispersion) at 5 years.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Anatomic stage I - III triple-negative breast cancer at diagnosis
Estrogen receptors (ER) and Progesterone receptors (PR) status <10%
Residual disease following at least 4 cycles of neoadjuvant chemotherapy. Patients who received other investigational immunotherapy or targeted therapy during the neoadjuvant phase of treatment are eligible.
≥ 18 years of age
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
All clinically significant toxic effects of prior cancer therapy resolved to Grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE, v 5.0), except alopecia and G2 neuropathy.
No evidence of metastatic disease.
A minimum 4-week wash out from previous chemotherapy treatment is required.
Adequate hematologic function: Absolute neutrophil count (ANC) ≥ 1,500 cells/μL (≥ 1,500/mm3); Platelets ≥ 100,000 cells/μL (≥ 100,000/mm3)
Adequate hepatic function: Bilirubin ≤ 1.5 times the specific institutional upper limit of normal (ULN). Exception: If Gilbert's syndrome; then ≤ 5 times ULN. Aspartate transaminase (AST) and alanine transaminase (ALT) each ≤ 2.5 x ULN
Adequate renal function: Serum creatinine ≤ 1.5 x ULN; or calculated creatinine clearance > 50 mL/min using the Cockcroft Gault formula.
Planned for 6 months or 8 cycles of adjuvant capecitabine.
Women of childbearing potential (WOCBP) must have a negative pregnancy test.
WOCBP must agree to use effective contraception during the study and for 3 months after the last dose.
Male participants and their female partners of child bearing potential must be willing to use an appropriate method of contraception during the study and for 3 months after the last dose.
Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and in the protocol